ArticleFrontiers in immunology2022
Defining Patient-Level Molecular Heterogeneity in Psoriasis Vulgaris Based on Single-Cell Transcriptomics.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Immunogenetics in psoriasis: towards personalised diagnosis and treatment strategies.Genes and immunity · 2026Review
- Multi‑omics and their integration in psoriasis research (Review).Molecular medicine reports · 2026Review
- Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology.Frontiers in immunology · 2026Review
- Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab.The Journal of allergy and clinical immunology · 2025Article
- Immunological profile of lactate metabolism-related genes in Psoriasis a comprehensive analysis based on bulk and single-cell RNA sequencing data.Scientific reports · 2025Article
- CHN1 as a potential predictive genetic biomarker for atopic dermatitis-related depression.Frontiers in immunology · 2025Article
- Beyond the dichotomy: understanding the overlap between atopic dermatitis and psoriasis.Frontiers in immunology · 2025Review
- Psoriasis vulgaris leaves a dynamic imprint on circulating and skin γδ TCR repertoires shaped by disease severity, age, and sex.Frontiers in immunology · 2025Article
- Characterization of the TCRβ repertoire of peripheral MR1-restricted MAIT cells in psoriasis vulgaris patients.Scientific reports · 2023Article
- Assessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology.The Journal of investigative dermatology · 2023Review
- Transcriptional regulation on effector T cells in the pathogenesis of psoriasis.European journal of medical research · 2023Review
- Multi-omics segregate different transcriptomic impacts of anti-IL-17A blockade on type 17 T-cells and regulatory immune cells in psoriasis skin.Frontiers in immunology · 2023Article
- Establishment and validation of evaluation models for post-inflammatory pigmentation abnormalities.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
Abstract
Identifying genetic variation underlying human diseases establishes targets for therapeutic development and helps tailor treatments to individual patients. Large-scale transcriptomic profiling has extended the study of such molecular heterogeneity between patients to somatic tissues. However, the lower resolution of bulk RNA profiling, especially in a complex, composite tissue such as the skin, has limited its success. Here we demonstrate approaches to interrogate patient-level molecular variance in a chronic skin inflammatory disease, psoriasis vulgaris, leveraging single-cell RNA-sequencing of CD45
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.